Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05041322 · ClinicalTrials.gov registry record · Phase 2

Improving Ventilatory Capacity in Those With Chronic High Level SCI

A Phase 2 study of Spinal Cord Injuries, sponsored by Spaulding Rehabilitation Hospital.

Completed
Registry status
Phase 2
Development phase
13
Enrollment target
1
Study location

NCT05041322: Completed Phase 2 study of Spinal Cord Injuries, sponsored by Spaulding Rehabilitation Hospital.

NCT05041322 is a Phase 2 study of Spinal Cord Injuries that has completed, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 13 participants, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05041322, a Phase 2 study of Spinal Cord Injuries, has completed, sponsored by Spaulding Rehabilitation Hospital.

COMPLETED
Registry status
Phase 2
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.

Primary Outcome

Forced expiratory volume over 1 second (FEV1).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Buspirone

Study Locations (1)

Massachusetts

  • Spaulding Hospital Cambridge - Cambridge

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2020-11-29
Est. Completion 2024-11-01
Phase Phase 2
Spaulding Rehabilitation Hospital

101 total trials

What the finished NCT05041322 record still lists

NCT05041322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05041322 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05041322 about?

NCT05041322 is a clinical study titled "Improving Ventilatory Capacity in Those With Chronic High Level SCI". The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.

What is the current status of trial NCT05041322?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-11-29. Estimated completion is 2024-11-01.

What conditions does trial NCT05041322 study?

This clinical trial studies the following conditions: Spinal Cord Injuries.

What interventions are being tested in trial NCT05041322?

The interventions under investigation include: Placebo (DRUG), Buspirone (DRUG).

Who is sponsoring clinical trial NCT05041322?

This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05041322 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05041322's enrollment target sits among peer trials

13 162nd of 202 higher than 39 of 202 other Spinal Cord Injuries trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05041322, the US trial registry maintained by the National Library of Medicine. NCT05041322 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.